Fondaparinux or enoxaparin: A comparative study of postoperative bleeding in coronary artery bypass grafting surgery

Abstract Objectives. Preoperative treatment with anti-coagulants for patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) exposes patients undergoing surgical revascularization to a higher risk of perioperative bleeding. The aim of this study was to compare the effect on bleeding and transfusion needs during cardiac surgery for patients treated with enoxaparin or fondaparinux. Design. Using a combined retrospective and prospective approach, we studied the outcome of 147 patients with NSTE-ACS referred to coronary artery bypass grafting in terms of bleeding, blood transfusions and other complications. Results. Eighty patients were treated preoperatively with enoxaparin, and 67 patients with fondaparinux. There was no significant difference in postoperative bleeding (532 ± 355 for enoxaparin group vs. 580 ± 300 ml for fondaparinux group, p = ns) or transfusion needs for the two groups. A subgroup analysis of the fondaparinux group showed a significantly higher amount of postoperative bleeding after 12 h for patients when preoperative treatment with fondaparinux was discontinued less than 36 h prior to surgery compared to more than 36 h. Discussion. This study suggests that preoperative treatment with fondaparinux for NSTE-ACS is as safe as enoxaparin in terms of postoperative bleeding and transfusion needs. Findings support discontinuation of fondaparinux at 36 h prior to surgery.

[1]  Neykova Anna,et al.  The HIT treatment in a cardiac surgery patient. , 2010, International journal of cardiology.

[2]  I. Ennker,et al.  Preoperative platelet inhibition with ASA does not influence postoperative blood loss following coronary artery bypass grafting. , 2009, The Thoracic and cardiovascular surgeon.

[3]  Yang Xiao-ming The effect of inhalation anesthetics on myocardial protection in coronary artery bypass grafting-a meta analysis , 2009 .

[4]  S. Steinhubl,et al.  Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. , 2008, Journal of the American College of Cardiology.

[5]  S. Bates,et al.  Delayed‐onset HIT caused by low‐molecular‐weight heparin manifesting during fondaparinux prophylaxis , 2008, American journal of hematology.

[6]  D. Mark,et al.  Clopidogrel use and bleeding after coronary artery bypass graft surgery. , 2008, American heart journal.

[7]  C. Hamm,et al.  Guidelines for anticoagulant use in acute coronary syndromes , 2008, The Lancet.

[8]  G. Guyatt,et al.  Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[9]  G. Guyatt,et al.  Guidelines for anticoagulant use in acute coronary syndromes , 2008, The Lancet.

[10]  A. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit , 2008 .

[11]  J. Bassand The place of fondaparinux in the ESC and ACC/AHA guidelines for anticoagulation in patients with non-ST elevation acute coronary syndromes , 2008 .

[12]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[13]  S. Yusuf,et al.  Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. , 2007, Journal of the American College of Cardiology.

[14]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[15]  Y. Choi,et al.  Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. , 2007, The Journal of thoracic and cardiovascular surgery.

[16]  J. Bassand,et al.  Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm. , 2007, European heart journal.

[17]  D. Torchiana,et al.  Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. , 2007, The Annals of thoracic surgery.

[18]  J. Dunning,et al.  Should clopidogrel be stopped prior to urgent cardiac surgery? , 2006, Interactive cardiovascular and thoracic surgery.

[19]  Fondaparinux versus enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[20]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[21]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[22]  A. Darzi,et al.  Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis , 2005, Heart.

[23]  M. Kuduvalli,et al.  Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  J. Kelton,et al.  Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. , 2005, Blood.

[25]  W. Byerly,et al.  Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. , 2003, The Annals of thoracic surgery.

[26]  A. Siegbahn,et al.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.

[27]  J S Alpert,et al.  Acute coronary syndromes. , 1997, Cardiology.